LINAGLIPTIN

LINAGLIPTIN · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 20, 2026

166 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (63)

Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Sep 5, 2031patentUS 8853156*PED
Mar 5, 2031formulationUS 88531564.7y
Dec 4, 2030patentUS 8846695*PED4.4y
Dec 4, 2030patentUS 8846695*PED4.4y
Dec 4, 2030patentUS 8846695*PED4.4y
Dec 4, 2030patentUS 8846695*PED4.4y
Nov 21, 2030patentUS 9155705*PED4.4y
Nov 21, 2030patentUS 9155705*PED4.4y
Nov 21, 2030patentUS 9155705*PED4.4y
Jun 4, 2030method-of-use (U-1503)US 88466953.9y
Jun 4, 2030method-of-use (U-1503)US 88466953.9y
May 21, 2030formulationUS 91557053.9y
May 21, 2030formulationUS 91557053.9y
May 21, 2030formulationUS 91557053.9y
Apr 10, 2030method-of-use (U-3854)US 119113883.8y
Apr 10, 2030method-of-use (U-3854)US 119113883.8y
Apr 10, 2030method-of-use (U-3854)US 119113883.8y
Apr 10, 2030method-of-use (U-3854)US 119113883.8y
Feb 5, 2030patentUS 10034877*PED3.6y
Feb 5, 2030patentUS 9486526*PED3.6y
Oct 2, 2029patentUS 10022379*PED3.2y
Oct 2, 2029patentUS 10022379*PED3.2y
Oct 2, 2029patentUS 10022379*PED3.2y
Oct 2, 2029patentUS 10973827*PED3.2y
Oct 2, 2029patentUS 10973827*PED3.2y
Oct 2, 2029patentUS 10973827*PED3.2y
Oct 2, 2029patentUS 9415016*PED3.2y
Oct 2, 2029patentUS 9415016*PED3.2y
Oct 2, 2029patentUS 9415016*PED3.2y
Aug 5, 2029method-of-use (U-2347)US 100348773.1y
Aug 5, 2029method-of-use (U-1915)US 94865263.1y
Apr 2, 2029method-of-use (U-2339)US 100223792.7y
Apr 2, 2029method-of-use (U-2339)US 100223792.7y
Apr 2, 2029method-of-use (U-2339)US 100223792.7y
Apr 2, 2029formulationUS 109738272.7y
Apr 2, 2029formulationUS 109738272.7y
Apr 2, 2029formulationUS 109738272.7y
Apr 2, 2029formulationUS 94150162.7y
Apr 2, 2029formulationUS 94150162.7y
Apr 2, 2029formulationUS 94150162.7y
Nov 4, 2027patentUS 11033552*PED1.3y
Nov 4, 2027patentUS 8673927*PED1.3y
Nov 4, 2027patentUS 8673927*PED1.3y
Nov 4, 2027patentUS 8673927*PED1.3y
Nov 4, 2027patentUS 8673927*PED1.3y
May 4, 2027formulationUS 11033552301d
May 4, 2027formulationUS 12178819301d
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805

FDA exclusivities (8)

Dec 20, 2026PEDPediatric (6mo bonus)166d
Dec 20, 2026PEDPediatric (6mo bonus)166d
Dec 20, 2026PEDPediatric (6mo bonus)166d
Dec 20, 2026PEDPediatric (6mo bonus)166d
Jun 20, 2026M-295Method (3y)
Jun 20, 2026M-295Method (3y)
Jun 20, 2026

LINAGLIPTIN

indications

all catalysts(4)

News(0)

Patent cliff

patents (63)

FDA exclusivities (8)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying LINAGLIPTIN